Analysts Recommendations BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX): Enerplus Corporation(NYSE:ERF)

0
3

BioCryst Pharmaceuticals, Inc. (BCRX) will report its next earnings on Mar 02 BMO. The company reported the earnings of $-0.34/Share in the last quarter where the estimated EPS by analysts was $-0.32/share. The difference between the expected and actual EPS was $-0.02/share, which represents an Earnings surprise of -6.3%.

Many analysts are providing their Estimated Earnings analysis for BioCryst Pharmaceuticals, Inc. and for the current quarter 9 analysts have projected that the stock could give an Average Earnings estimate of $-0.26/share. These analysts have also projected a Low Estimate of $-0.39/share and a High Estimate of $-0.05/share.

In case of Revenue Estimates, 8 analysts have provided their consensus Average Revenue Estimates for BioCryst Pharmaceuticals, Inc. as 9.88 Million. According to these analysts, the Low Revenue Estimate for BioCryst Pharmaceuticals, Inc. is 1.9 Million and the High Revenue Estimate is 30 Million. The company had Year Ago Sales of 2.73 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for BCRX to be 0%. They are projecting Next Quarter growth of -7.14%. For the next 5 years, BioCryst Pharmaceuticals, Inc. is expecting Growth of 11.9% per annum, whereas in the past 5 years the growth was -23.47% per annum.

Some buy side analysts are also providing their Analysis on BioCryst Pharmaceuticals, Inc., where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 1 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

The Relative Volume of the company is 0.84 and Average Volume (3 months) is 3.84 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -107.8%. The Return on Equity (ROE) value stands at 0%. While it’s Return on Investment (ROI) value is -84.9%.

While looking at the Stock’s Performance, BioCryst Pharmaceuticals, Inc. currently shows a Weekly Performance of -3.95%, where Monthly Performance is 2.28%, Quarterly performance is 52.62%, 6 Months performance is 3% and yearly performance percentage is -67.93%. Year to Date performance value (YTD perf) value is -15.51%. The Stock currently has a Weekly Volatility of 5.00% and Monthly Volatility of 8.58%.

Enerplus Corporation (ERF) will report its next earnings on Feb 21 BMO. The company reported the earnings of $0.06/Share in the last quarter where the estimated EPS by analysts was $0.07/share. The difference between the expected and actual EPS was $-0.01/share, which represents an Earnings surprise of -14.3%.

Many analysts are providing their Estimated Earnings analysis for Enerplus Corporation and for the current quarter 4 analysts have projected that the stock could give an Average Earnings estimate of $0.11/share. These analysts have also projected a Low Estimate of $0.03/share and a High Estimate of $0.14/share.

In case of Revenue Estimates, 2 analysts have provided their consensus Average Revenue Estimates for Enerplus Corporation as 224.81 Million. According to these analysts, the Low Revenue Estimate for Enerplus Corporation is 188.88 Million and the High Revenue Estimate is 260.74 Million. The company had Year Ago Sales of 150.23 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for ERF to be -40.6%. They are projecting Next Quarter growth of -26.09%. For the next 5 years, Enerplus Corporation is expecting Growth of 15.75% per annum, whereas in the past 5 years the growth was -33.03% per annum.

Some buy side analysts are also providing their Analysis on Enerplus Corporation, where 8 analysts have rated the stock as Strong buy, 4 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

The Relative Volume of the company is 1.08 and Average Volume (3 months) is 1.33 million. The company’s P/E (price to earnings) ratio is 3.97 and Forward P/E ratio of 6.28.

The company shows its Return on Assets (ROA) value of 13.5%. The Return on Equity (ROE) value stands at 21.3%. While it’s Return on Investment (ROI) value is 13.6%.

While looking at the Stock’s Performance, Enerplus Corporation currently shows a Weekly Performance of -0.38%, where Monthly Performance is -22.32%, Quarterly performance is -18.44%, 6 Months performance is -20.43% and yearly performance percentage is -35.4%. Year to Date performance value (YTD perf) value is -26.79%. The Stock currently has a Weekly Volatility of 4.23% and Monthly Volatility of 4.35%.

SHARE